Affinity of human IgG subclasses to mouse Fc gamma receptors
- PMID: 28463043
- PMCID: PMC5524164
- DOI: 10.1080/19420862.2017.1323159
Affinity of human IgG subclasses to mouse Fc gamma receptors
Abstract
Human IgG is the main antibody class used in antibody therapies because of its efficacy and longer half-life, which are completely or partly due to FcγR-mediated functions of the molecules. Preclinical testing in mouse models are frequently performed using human IgG, but no detailed information on binding of human IgG to mouse FcγRs is available. The orthologous mouse and human FcγRs share roughly 60-70% identity, suggesting some incompatibility. Here, we report binding affinities of all mouse and human IgG subclasses to mouse FcγR. Human IgGs bound to mouse FcγR with remarkably similar binding strengths as we know from binding to human ortholog receptors, with relative affinities IgG3>IgG1>IgG4>IgG2 and FcγRI>>FcγRIV>FcγRIII>FcγRIIb. This suggests human IgG subclasses to have similar relative FcγR-mediated biological activities in mice.
Keywords: Fc-receptors; FcγR; IgG subclasses; mouse models; surface plasmon resonance.
Figures



Similar articles
-
Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.J Immunol. 2017 Jul 1;199(1):204-211. doi: 10.4049/jimmunol.1700116. Epub 2017 May 31. J Immunol. 2017. PMID: 28566370
-
Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors.Immunol Lett. 2018 May;197:1-8. doi: 10.1016/j.imlet.2018.02.006. Epub 2018 Feb 21. Immunol Lett. 2018. PMID: 29476755
-
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17. Methods. 2014. PMID: 23872058
-
Interaction sites on human IgG-Fc for FcgammaR: current models.Immunol Lett. 2002 Jun 3;82(1-2):57-65. doi: 10.1016/s0165-2478(02)00019-6. Immunol Lett. 2002. PMID: 12008035 Review.
-
How to select IgG subclasses in developing anti-tumor therapeutic antibodies.J Hematol Oncol. 2020 May 5;13(1):45. doi: 10.1186/s13045-020-00876-4. J Hematol Oncol. 2020. PMID: 32370812 Free PMC article. Review.
Cited by
-
Factor IX administration in the skin primes inhibitor formation and sensitizes hemophilia B mice to systemic factor IX administration.Res Pract Thromb Haemost. 2023 Nov 4;7(8):102248. doi: 10.1016/j.rpth.2023.102248. eCollection 2023 Nov. Res Pract Thromb Haemost. 2023. PMID: 38193070 Free PMC article.
-
Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in mice.Nat Commun. 2024 Feb 23;15(1):1665. doi: 10.1038/s41467-024-45526-2. Nat Commun. 2024. PMID: 38396019 Free PMC article.
-
Association Between Cytokeratin 19-Specific IgG and Neutrophil Activation in Asthma.Allergy Asthma Immunol Res. 2024 Jul;16(4):353-371. doi: 10.4168/aair.2024.16.4.353. Allergy Asthma Immunol Res. 2024. PMID: 39155736 Free PMC article.
-
Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA.Front Immunol. 2023 Feb 2;14:1037033. doi: 10.3389/fimmu.2023.1037033. eCollection 2023. Front Immunol. 2023. PMID: 36817447 Free PMC article. Review.
-
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.bioRxiv [Preprint]. 2023 Mar 9:2022.01.23.477397. doi: 10.1101/2022.01.23.477397. bioRxiv. 2023. Update in: Microbiol Spectr. 2024 Aug 6;12(8):e0391623. doi: 10.1128/spectrum.03916-23. PMID: 35118468 Free PMC article. Updated. Preprint.
References
-
- Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 2015; 15:361-70; PMID:25998715; https://doi.org/10.1038/nrc3930 - DOI - PMC - PubMed
-
- Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26:513-33; PMID:18370923; https://doi.org/10.1146/annurev.immunol.26.021607.090232 - DOI - PubMed
-
- Barahona Afonso AF, João CMP. The production processes and biological effects of intravenous immunoglobulin. Biomolecules 2016; 6:15; PMID:27005671; https://doi.org/10.3390/biom6010015 - DOI - PMC - PubMed
-
- Loisel S, Ohresser M, Pallardy M, Daydé D, Berthou C, Cartron G, Watier H. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007; 62:34-42; PMID:17197192; https://doi.org/10.1016/j.critrevonc.2006.11.010 - DOI - PubMed
-
- Cheon D-J, Orsulic S. Mouse models of cancer. Annu Rev Pathol 2011; 6:95-119; PMID:20936938; https://doi.org/10.1146/annurev.pathol.3.121806.154244 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources